Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eric H Rubin

Showing results (21-30 of 66) with videos related to

Pageof 7
Sort By:
Contemporary Clinical Trials|November 2, 2022
Assessment of added activity of an antitumor agentCong Chen, Linda Zhiping Sun, Yixin Ren, et al.
Investigational New Drugs|October 19, 2007
Effects of drug efflux proteins and topoisomerase I mutations on the camptothecin analogue gimatecanMurugesan K Gounder, Ahamed S Nazar, Ahamed Saleem, et al.
Cancer Chemotherapy and Pharmacology|July 4, 2013
Clinical pharmacology profile of vorinostat, a histone deacetylase inhibitorMarian Iwamoto, Evan J Friedman, Punam Sandhu, et al.
JAMA Oncology|July 21, 2022
Log-Rank Test vs MaxCombo and Difference in Restricted Mean Survival Time Tests for Comparing Survival Under Nonproportional Hazards in Immuno-oncology Trials: A Systematic Review and Meta-analysisPralay Mukhopadhyay, Jiabu Ye, Keaven M Anderson, et al.
The Journal of Biological Chemistry|December 14, 2007
Ubiquitination by TOPORS regulates the prostate tumor suppressor NKX3.1Bin Guan, Pooja Pungaliya, Xiang Li, et al.
Journal of Proteome Research|September 7, 2007
TOPORS functions as a SUMO-1 E3 ligase for chromatin-modifying proteinsPooja Pungaliya, Diptee Kulkarni, Hye-Jin Park, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 3, 2017
From Famine to Feast: Developing Early-Phase Combination Immunotherapy Trials WiselyDaphne Day, Arta M Monjazeb, Elad Sharon, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 3, 2016
Rendering the 3 + 3 Design to Rest: More Efficient Approaches to Oncology Dose-Finding Trials in the Era of Targeted TherapyLei Nie, Eric H Rubin, Nitin Mehrotra, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 23, 2005
Phase I dose-finding study of weekly single-agent patupilone in patients with advanced solid tumorsEric H Rubin, John Rothermel, Fisseha Tesfaye, et al.
Oncogene|July 13, 2019
Correction: The topoisomerase I- and p53-binding protein topors is differentially expressed in normal and malignant human tissues and may function as a tumor suppressorAhamed Saleem, Jayeeta Dutta, Diptee Malegaonkar, et al.
Pageof 7

Showing results (21-30 of 66) with videos related to

Sort By:
Pageof 7
Contemporary Clinical Trials|November 2, 2022
Assessment of added activity of an antitumor agentCong Chen, Linda Zhiping Sun, Yixin Ren, et al.
Investigational New Drugs|October 19, 2007
Effects of drug efflux proteins and topoisomerase I mutations on the camptothecin analogue gimatecanMurugesan K Gounder, Ahamed S Nazar, Ahamed Saleem, et al.
Cancer Chemotherapy and Pharmacology|July 4, 2013
Clinical pharmacology profile of vorinostat, a histone deacetylase inhibitorMarian Iwamoto, Evan J Friedman, Punam Sandhu, et al.
JAMA Oncology|July 21, 2022
Log-Rank Test vs MaxCombo and Difference in Restricted Mean Survival Time Tests for Comparing Survival Under Nonproportional Hazards in Immuno-oncology Trials: A Systematic Review and Meta-analysisPralay Mukhopadhyay, Jiabu Ye, Keaven M Anderson, et al.
The Journal of Biological Chemistry|December 14, 2007
Ubiquitination by TOPORS regulates the prostate tumor suppressor NKX3.1Bin Guan, Pooja Pungaliya, Xiang Li, et al.
Journal of Proteome Research|September 7, 2007
TOPORS functions as a SUMO-1 E3 ligase for chromatin-modifying proteinsPooja Pungaliya, Diptee Kulkarni, Hye-Jin Park, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 3, 2017
From Famine to Feast: Developing Early-Phase Combination Immunotherapy Trials WiselyDaphne Day, Arta M Monjazeb, Elad Sharon, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 3, 2016
Rendering the 3 + 3 Design to Rest: More Efficient Approaches to Oncology Dose-Finding Trials in the Era of Targeted TherapyLei Nie, Eric H Rubin, Nitin Mehrotra, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 23, 2005
Phase I dose-finding study of weekly single-agent patupilone in patients with advanced solid tumorsEric H Rubin, John Rothermel, Fisseha Tesfaye, et al.
Oncogene|July 13, 2019
Correction: The topoisomerase I- and p53-binding protein topors is differentially expressed in normal and malignant human tissues and may function as a tumor suppressorAhamed Saleem, Jayeeta Dutta, Diptee Malegaonkar, et al.
Pageof 7